BACKGROUND
Gastric cancer is of major importance worldwide, being the second most common cause of cancer-related death in the world [1] . Despite its decreasing incidence, gastric cancer is still a challenging disease. Apart from countries with established national screening programs like Japan and Korea, gastric cancer patients are often diagnosed with advanced tumours and their prognoses remain poor. Conventional systemic chemotherapy when combined with surgical tumour resection yields only modest improvement in survival for patients with resectable gastric cancer [2] . The knowledge of molecular pathways implicated in gastric cancer pathogenesis is still in its infancy and the contribution of molecular biology to the development of new-targeted therapies in gastric cancer is far behind other more common cancers such as breast, colon or lung [3] .
The phosphatidylinositide 3-kinase (PI3K) pathway is an important intracellular pathway that is frequently activated in cancer cells [4, 5] . Increased levels of phosphorylated AKT (pAKT), downstream of PI3K signaling, and low expression or mutation of PTEN, a negative regulator of PI3K signaling, have been shown to be involved in breast, ovarian and colon cancers [5] [6] [7] . This has led to the emergence of PI3K inhibitors as potential new treatment modalities [8] .
Alterations in the PI3K pathway have been documented in several gastric cancer studies [9] [10] [11] [12] [13] , although, these are limited in their sample size or vary significantly in the prevalence of PIK3CA mutations. Furthermore, little additional work has been performed on clinicopathologic correlates of PIK3CA in this tumour type. Similarly, reports on PIK3CA amplification and AKT mutation are limited with only a few reports published to date [9, 10] .
It is also not well understood how PIK3CA amplification qualitatively or quantitatively pathway. We therefore undertook a retrospective study to investigate the frequency of molecular changes in the PI3K pathway in gastric cancer. Cell block preparation. Cell blocks were prepared as described previously [15] . Briefly, cells were cultured in a T75 flask until 70-90% of confluence. After washing with PBS, trypsinising and spinning down the cells, the cell pellet was fixed with 1 ml of 10% neutral buffered formalin for 10 min, resuspended in 50µl of pre-warmed 4% nutrient agar, and placed at 4°C to form a suspended cell block. Finally, the cell block was transferred to a tissue cassette and embedded in paraffin.
MATERIALS AND METHODS

Materials
Immunohistochemistry. The TMA slides were de-waxed and hydrated through graded alcohol and distilled water using an autostainer . Antigen retrieval was done using EnVision TM Target
Retrieval Solution (Dako Australia, Campbellfield, Victoria, Australia), at high pH in a pressure cooker. Immunohistochemical staining was performed using primary antibodies and 
Where a=1 for mutually non-exclusive drugs, (D)1 and (D)2 are the doses of the separate drugs and the combination, and (Dx)1 and (Dx)2 are the doses resulting in a growth inhibition of x%. A CI of < 0.9, 0.9-1.1, or > 1.1 indicates synergism, additivity, or antagonism respectively.
RESULTS
PI3K alterations in gastric cancer tissues
A total of 61 human gastric cancer samples were analysed for alterations in various components of the PI3K pathway (Table I) .
DNA extracted from the samples was screened for somatic mutations in exons 9 and 20 of PIK3CA and exon 4 of AKT1, and for PIK3CA copy number. Three missense PIK3CA mutations were identified (4.9% of tumours); one of the mutations was identified in exon 9
(c.1615C>T; p.P539S) and two were found in exon 20 (c.3140A>G: p.H1047R) ( Table 1) .
No mutations were detected in corresponding adjacent non-malignant mucosa indicating that the mutations are somatic. Two tumours were found to harbour silent somatic changes in exon 20 (c.3075C>T; p.T1025T) but as this sequence change does not alter the protein PIK3CA copy number gains were detected in 8 of 61 (13.1%) gastric tumour samples ( Table   1) . Seven of the 8 samples with copy number gain also had high (above average) p110α
protein expression. None of the tumours with a PIK3CA copy number gain harboured a PIK3CA mutation.
Immunohistochemistry was used to assess the level of PTEN protein expression in 61 gastric tumours and identified 24 (39%) with loss of PTEN protein (Figure 1) . Interestingly, two of these tumours also had PIK3CA copy number gain but none harboured a PIK3CA mutation (Table 1) .
pAKT levels were examined as a surrogate marker for PI3K pathway activity. Twenty eight tumours (46%) were classed as having high pAKT levels ( Figure 1 ). These included 6 of the 8 tumours with PIK3CA gain and 2 of the 3 with PIK3CA mutation. Interestingly, loss of PTEN was significantly associated with low pAKT (Table II) .
The changes in PI3K pathway were compared to clinical features of the tumours (Table III) .
Interestingly, there was an association with tumour location with tumours in the cardia having significantly less alterations in the PI3K pathway than non-cardia tumours (p=0.03).
No other significant clinical associations were found but this may be a reflection of the relatively small numbers of PI3K alterations in some groups resulting in limited statistical power to detect differences (type II error).
PI3K alterations in gastric cancer cell lines
The genetic alterations related to PI3K pathway were also examined in nine human gastric cancer cell lines. The AGS cell line was found to harbour the PIK3CA mutation c.1357G>A however, the significance of this change is unclear as this has been suggested to be due to the presence of a pseudogene on chromosome 22 [17, 18] .) PIK3CA copy number gains were identified in KATO-III, GTL-16 and Hs746T (Table IV) . All three of the cell lines with PIK3CA gain had above average expression of p110α protein as assessed by immunohistochemistry (data not shown).
The levels of pAKT and PTEN protein were also assessed by immunohistochemistry ( Figure   2 ). PTEN was found to be lost in 2 cell lines (SNU-16) and MKN-28). pAKT levels were found to be high in 6 of the 9 cell lines including all those with PIK3CA mutation or gain and one of the two with PTEN loss (Table IV) . Table V) .
Sensitivity of gastric cancer cell lines to the PI3K inhibitor LY294002.
Synergistic effects of PI3K inhibition with chemotherapeutic agents.
The combination of LY294002 with oxaliplatin and 5-FU were tested (using constant ratios between LY294002 and 5-FU or oxaliplatin) in cell lines with a computable IC 50 value. A synergistic effect was found in AGS and SNU-1 cell lines when 5-FU was combined with LY294002 (combination index <0.9 at effect dose of 75% and 90% growth inhibition).
Synergism was also detected between LY294002 and oxaliplatin in the Hs746T cell line ( Figure 4 , Table V ). [23] . The incidence of PIK3CA mutation found in gastric cancer in our study (4.9%) is lower than these but is consistent with previous reports by Li et al. [12] (4.3%) and Lee et al. (5.1%) [11] . In addition, in this study PIK3CA copy number gain was found to be more frequent (13.1%) than PIK3CA mutations. However, this prevalence was also lower than that previously reported in gastric cancer (36.4%) [9] .
A mutation in the AKT1 gene that results in E17K substitution in the PH domain of AKT1 has been recently reported in a number of human tumours including breast cancer (5/61; 8.2%), colorectal cancer (3/51; 5.9%) and ovarian cancer (1/50; 2%) [24] . It was also documented in endometrial cancer (2.2%; 2/89) [25] . However, we were unable to detect any E17K mutations in AKT1 in our gastric cancer cohort. This is consistent with the work of Kim et al., who examined a variety of tumour types and detected AKT1 E17K mutations in 4 of 93 breast cancers but none of 180 gastric adenocarcinomas [10] . Similarly, Soung et al. who found no AKT1 mutations (but 1 AKT2 mutation) in 51 gastric cancers [26] . [27] . Consistent with a previous report [9] , we detected PTEN loss in 24 of the 61 tumours (39%).
In general, the abnormalities detected in the PI3K pathway in our study were mutually exclusive. Only 2 tumours contained more than one alteration and both of these had PIK3CA gain and PTEN loss.
The overall activity of the PI3K pathway was assessed using the phosphorylation of AKT as a surrogate marker of PI3K pathway activity. The number of samples with PIK3CA mutations was too small to draw any conclusions regarding an association with pAKT levels but the 2 tumours with the common H1047R mutation both exhibited above average pAKT levels. Also, 6 of the 8 tumours with PIK3CA gain had high pAKT, as did the 3 cell lines with PIK3CA gain. Interestingly, the 2 tumours with PIK3CA gain that did not have high pAKT were those that had also lost PTEN (Table I) . Indeed, in general, PTEN loss was found to be significantly associated with low pAKT levels (p= 0.002, Table II ), a finding that is perhaps surprisingly given PTENs known role as a negative regulator of the PI3K pathway.
However, not only is the regulation of the PI3K pathway complex with abundant cross-talk and feed-back loops but Akt is not the only downstream effector of PI3K [28] . It is thus possible that in the absence of PTEN the increased PI3K activity in these tumours is directed through other alternative effector molecules.
Apart from an apparent preponderance of PI3K pathway abnormalities in the non-cardia gastric tumours, compared to tumours in the cardia, there were no significant clinical associations detected. However, it must be acknowledged that we cannot rule out the possibility that our sample numbers may be too small to detect clinically relevant associations (type II errors). We are also unable to comment on any potential association between PI3K changes and survival as we, unfortunately, did not have access to appropriate follow-up data.
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Activation of PI3K pathway in gastric cancer cell lines
In order to identify a model system in which to test potential therapeutic agents, we investigated the activation of the PI3K pathway in a series of established gastric cancer cell lines. Two thirds (6/9) of the cell lines had increased PI3K pathway activity as evidenced by high pAKT (Table IV) . In most cases this was consistent with the presence of a detectable molecular alteration in the PI3K pathway (PIK3CA mutation or copy number gain or PTEN loss). While this correlation was not absolute, it is possible that some of the cell lines may have PI3K pathway alterations that have not been identified in our limited screen.
Nevertheless, the overwhelming evidence for a role for the PI3K pathway activation in the initiation and/or progression of tumourigenesis makes the PI3K pathway a logical target for therapeutic intervention. Consistent with this, many of the cell lines tested in this study were found to be sensitive to the PI3K inhibitor LY294002 (Table IV) .
It is noteworthy that two of the gastric cancer cell lines (KATO-III and SNU-16) were found to be insensitive to LY294002 even though they have genetic abnormalities in the PI3K pathway and demonstrated upregulation of pAKT protein. This suggests that the presence of genetic abnormalities in the PI3K pathway may not necessarily be the optimal marker for sensitivity to PI3K inhibitors. Interestingly, both of these cell lines have previously been
shown to also harbor a p53 mutation [29, 30] . Recently, several studies have reported that LY294002 induces apoptosis in a p53-dependent manner [31] [32] [33] . Thus, p53 mutation might be a possible reason for the insensitivity to LY294002 in these cell lines.
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